Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.3541
Abstract: Importance Use of haploidentical (HAPLO) stem cell transplantation with posttransplant cyclophosphamide is rapidly increasing in adults with hematologic cancers. However, its specific role compared with other transplant strategies has yet to be identified. Objective To… read more here.
Keywords: posttransplant cyclophosphamide; cell transplantation; stem cell; cyclophosphamide ... See more keywords
Myeloablative Conditioning Regimen in Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide in Children With High-risk Hematologic Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002406
Abstract: Limited information is available on outcomes of haploidentical stem cell transplantation (haploSCT) with posttransplant cyclophosphamide using myeloablative conditioning regimens in children and adolescents. We report the results of a single-institution retrospective study of myeloablative haploSCT… read more here.
Keywords: hematologic malignancies; high risk; risk hematologic; myeloablative conditioning ... See more keywords
A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Cell Transplantation"
DOI: 10.1177/09636897221112098
Abstract: The optimal dose of posttransplant cyclophosphamide (PTCy) for use in patients undergoing HLA-haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide (PTCy-haplo) has not been sufficiently examined. This study evaluates the safety and efficacy of HLA-haploidentical hematopoietic… read more here.
Keywords: transplantation; posttransplant cyclophosphamide; hla haploidentical; cell transplantation ... See more keywords
NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-05-780668
Abstract: The use of posttransplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing safe infusion of unmanipulated T cell-replete grafts. PT-Cy selectively eliminates proliferating alloreactive T cells, but… read more here.
Keywords: mature cells; posttransplant cyclophosphamide; cell recovery; hsct ... See more keywords
Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide.
Sign Up to like & getrecommendations! Published in 2017 at "Blood advances"
DOI: 10.1182/bloodadvances.2017009423
Abstract: The establishment of safe approaches to attain durable donor-type chimerism and immune tolerance toward donor antigens represents a major challenge in transplantation biology. Haploidentical hematopoietic stem cell transplantation (HSCT) is currently used for cancer therapy… read more here.
Keywords: posttransplant cyclophosphamide; haploidentical hsct; immune tolerance; hsct ... See more keywords
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024015173
Abstract: Key Points • PPTCy-based GVHD prophylaxis leads to a low rate of aGVHD, a low incidence of NRM and acceptable relapse rate after HSCT from MMUD read more here.
Keywords: gvhd prophylaxis; cyclophosphamide gvhd; posttransplant cyclophosphamide; gvhd ... See more keywords
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2025015964
Abstract: Key Points • PTCy-based GVHD prophylaxis benefits adults aged ≥70 years with improved GVHD control and improved immunosuppression-free survival.• Overall, the benefit of PTCy translates to lower observed NRM and improved OS in this older… read more here.
Keywords: based gvhd; gvhd prophylaxis; impact posttransplant; posttransplant cyclophosphamide ... See more keywords